This study will evaluate the antiviral efficacy, safety and tolerability of sofosbuvir (SOF)/velpatasvir (VEL; GS-5816) fixed dose combination (FDC) administered for 12 weeks in HCV treatment-naive and treatment-experienced (including treatment intolerant) adults with chronic HCV infection who are coinfected with HIV-1.